A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib (Iressa) in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Who Have Progressed on Epidermal Growth Factor Receptor Inhibitor Treatment

Trial Profile

A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib (Iressa) in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Who Have Progressed on Epidermal Growth Factor Receptor Inhibitor Treatment

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Savolitinib (Primary) ; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 18 Oct 2017 Results (data cut off: March 2017, n=44) from phase Ib part of the study, presented at the 18th World Conference on Lung Cancer.
    • 17 Oct 2017 Results presented in an AstraZeneca media release.
    • 16 Oct 2017 According to an AstraZeneca media release, results from this trial were presented at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer (WCLC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top